Showing: 1 - 3 of 19 RESULTS
Announcements Banner News Niemann-Pick Type C News Research News

Azafaros Receives FDA’s IND Clearance and Fast Track Designation

Azafaros B.V. announced in January 2023 that it Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA) to conduct a clinical Phase 2 trial for its lead asset, AZ-3102, for the treatment of GM2 gangliosidosis (GM2) and Niemann-Pick disease type C (NP-C). In addition to the IND clearance, the FDA …